Most recently, CRI has launched a new «
venture philanthropy» program called the Cancer Vaccine Acceleration Fund (CVAF) as a means to catalyze development of next - generation therapeutic cancer vaccines and other immunotherapies by helping to address the critical shortage of
capital available for early
stage clinical trials.